(Q38152971)

29 August 2017

Clinical course of patients with Behçet's uveitis following discontinuation of infliximab therapy (English)

1 reference

29 August 2017

0 references

1 reference

Tatsushi Kawaguchi

1

1 reference

29 August 2017

Yuko Kawazoe

2

1 reference

29 August 2017

Koju Kamoi

3

1 reference

29 August 2017

Masaru Miyanaga

4

1 reference

29 August 2017

Hiroshi Takase

5

1 reference

29 August 2017

Sunao Sugita

6

1 reference

29 August 2017

Manabu Mochizuki

7

1 reference

29 August 2017

16 October 2013

1 reference

Japanese Journal of Ophthalmology

29 August 2017

1 reference

29 August 2017

58

1 reference

29 August 2017

1

1 reference

29 August 2017

75-80

1 reference

https://scigraph.springernature.com/pub.10.1007/s10384-013-0283-3

29 August 2017

0 references

1 reference

https://api.crossref.org/works/10.1007%2FS10384-013-0283-3

Uveitis in Behçet's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10384-013-0283-3

Ocular immunopathology of Behçet's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10384-013-0283-3

Risk and prognostic factors of poor visual outcome in Behcet's disease with ocular involvement

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10384-013-0283-3

Immunotherapy for Behçet's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10384-013-0283-3

Uveitis in Behçet disease: an analysis of 880 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10384-013-0283-3

Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behçet's disease: an open-label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10384-013-0283-3

Comparison of infliximab versus ciclosporin during the initial 6-month treatment period in Behçet disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10384-013-0283-3

Regression of optic disc neovascularization in patients with Behçet's uveoretinitis after infliximab therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10384-013-0283-3

Multicenter study of infliximab for refractory uveoretinitis in Behçet disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10384-013-0283-3

Intraocular cytokine environment in active Behçet uveitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10384-013-0283-3

Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10384-013-0283-3

Infections in patients with rheumatoid arthritis treated with biologic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10384-013-0283-3

Anti-tumor necrosis factor therapy and Listeria monocytogenes infection: report of two cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10384-013-0283-3

Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10384-013-0283-3

Psoriasis triggered by infliximab in a patient with Behçet's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10384-013-0283-3

A prospective trial of infliximab therapy for refractory uveitis: preliminary safety and efficacy outcomes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10384-013-0283-3

Maintenance of remission with infliximab in inflammatory bowel disease: efficacy and safety long-term follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10384-013-0283-3

Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: Results from a twe

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10384-013-0283-3

Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10384-013-0283-3

Anti-TNF-alpha therapy induces a distinct regulatory T cell population in patients with rheumatoid arthritis via TGF-beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10384-013-0283-3

Invasive Pulmonary Aspergillosis Associated with Infliximab Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10384-013-0283-3

Effects of infliximab in the treatment of refractory posterior uveitis of Behçet’s disease after withdrawal of infusions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10384-013-0283-3

Decreased ocular inflammatory attacks and background retinal and disc vascular leakage in patients with Behcet's disease on infliximab therapy

21 January 2018

1 reference

12 December 2020

Anti-tumor necrosis factor alpha therapy suppresses the induction of experimental autoimmune uveoretinitis in mice by inhibiting antigen priming

1 reference

12 December 2020

Clinical background comparison of patients with and without ocular inflammatory attacks after initiation of infliximab therapy

1 reference

12 December 2020

The incidence and management of infusion reactions to infliximab: a large center experience

1 reference

12 December 2020

Long-term safety and efficacy of infliximab therapy in refractory uveitis due to Behçet's disease

1 reference

12 December 2020

Miliary tuberculosis after biological therapy for rheumatoid arthritis

1 reference

12 December 2020

Long-term efficacy of infliximab in refractory posterior uveitis of Behcet's disease: a 24-month follow-up study

1 reference

12 December 2020

Cytokine mRNA levels in rat ocular tissues after systemic endotoxin treatment.

1 reference

12 December 2020

Psoriasis induced by anti-tumor necrosis factor therapy: a paradoxical adverse reaction

1 reference

12 December 2020

Behçet's disease: an update on the pathogenesis

1 reference

12 December 2020

Tumour necrosis factor-induced uveitis in the Lewis rat is associated with intraocular interleukin 6 production

1 reference

12 December 2020

Infliximab treatment for ocular and extraocular manifestations of Behçet's disease

1 reference

12 December 2020

Safety and efficacy of readministration of infliximab after longterm continuous therapy and withdrawal in patients with ankylosing spondylitis

1 reference

12 December 2020

Can remission be maintained with or without further drug therapy in rheumatoid arthritis?

1 reference

12 December 2020

Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behçet's disease with refractory uveoretinitis

1 reference

12 December 2020

Induction of regulatory T cells by infliximab in Behcet's disease

1 reference

12 December 2020

10.1007/S10384-013-0283-3

Identifiers

DOI

1 reference

Dimensions Publication ID

29 August 2017

0 references

1 reference